phenlarmide (FLZ)
/ Shijiazhuang Yiling Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
January 03, 2022
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
(clinicaltrials.gov)
- P1; N=40; Completed; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd; Not yet recruiting ➔ Completed; Trial primary completion date: Jun 2021 ➔ Oct 2021
Clinical • Trial completion • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
December 14, 2021
A Clinical Study Trial of Phenlarmide in China
(clinicaltrials.gov)
- P1; N=36; Completed; Sponsor: Yiling Pharmaceutical Inc.; Recruiting ➔ Completed
Clinical • Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease
January 05, 2021
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
(clinicaltrials.gov)
- P1; N=40; Not yet recruiting; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
Clinical • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
November 24, 2020
A Clinical Study Trial of Phenlarmide in China
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Yiling Pharmaceutical Inc.; Trial completion date: Oct 2020 ➔ Jan 2021
Clinical • Trial completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
July 02, 2020
A Clinical Study Trial of Phenlarmide in China
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Yiling Pharmaceutical Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease
1 to 5
Of
5
Go to page
1